Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Qyuns Therapeutics Co., Ltd. Class H ( (HK:2509) ) has provided an announcement.
Qyuns Therapeutics Co., Ltd. has announced an Extraordinary General Meeting (EGM) scheduled for December 19, 2025, to discuss and approve key resolutions. These include the renewal of the New Annual Caps for financial years 2026 to 2028 under the QX001S Framework Agreement and proposed amendments to the articles of association. The outcomes of this meeting could significantly impact the company’s operational strategies and governance structure, potentially influencing its market positioning and stakeholder interests.
The most recent analyst rating on (HK:2509) stock is a Hold with a HK$22.00 price target. To see the full list of analyst forecasts on Qyuns Therapeutics Co., Ltd. Class H stock, see the HK:2509 Stock Forecast page.
More about Qyuns Therapeutics Co., Ltd. Class H
Qyuns Therapeutics Co., Ltd. is a joint stock company incorporated in the People’s Republic of China, operating within the pharmaceutical industry. The company focuses on developing therapeutic solutions and is listed on the Hong Kong Stock Exchange.
Average Trading Volume: 791,429
Technical Sentiment Signal: Buy
Current Market Cap: HK$4.93B
Learn more about 2509 stock on TipRanks’ Stock Analysis page.